News stories about Dextera Surgical (NASDAQ:DXTR) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dextera Surgical earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.9149366395572 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of equities research analysts recently issued reports on the company. Zacks Investment Research raised Dextera Surgical from a “sell” rating to a “hold” rating in a research report on Friday, June 30th. Wedbush cut their target price on Dextera Surgical from $3.50 to $0.70 and set an “outperform” rating on the stock in a research note on Wednesday, July 12th. Finally, Ladenburg Thalmann Financial Services assumed coverage on Dextera Surgical in a research report on Wednesday, August 16th. They set a “buy” rating and a $0.80 price target for the company.

Shares of Dextera Surgical (NASDAQ:DXTR) traded down 6.5241% on Monday, reaching $0.2579. 2,763,089 shares of the company traded hands. The company’s market capitalization is $4.59 million. The firm has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.51. Dextera Surgical has a one year low of $0.17 and a one year high of $2.33.

Dextera Surgical (NASDAQ:DXTR) last issued its earnings results on Tuesday, August 8th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.29). The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.03 million. Equities analysts forecast that Dextera Surgical will post ($0.24) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/02/dextera-surgical-dxtr-given-news-impact-score-of-0-13.html.

About Dextera Surgical

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Insider Buying and Selling by Quarter for Dextera Surgical (NASDAQ:DXTR)

Receive News & Stock Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related stocks with our FREE daily email newsletter.